Catalent Implements Optofluidic Platform for Cell-Line Development

Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletterPharmaceutical Technology\'s In the Lab eNewsletter-08-01-2018
Volume 13
Issue 8

Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.

Catalent Pharma Solutions and Berkeley Lights announced in a July 10, 2018 press release that Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.

The Beacon platform is capable of screening thousands of clones in parallel and identifying top-producing clones in five days. According to Catalent, automating the process on the platform provides additional insights into the behavior of clonal populations that are currently unavailable using traditional techniques. 

The four integrated workflows of the platform-import, culture, assay, and export-will be applied to Catalent Biologics’ GPEx cell-line development platform as well as Catalent’s ongoing research and development activities.

Source: Catalent Pharma Solutions

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Related Content